Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic

Vor Biopharma secured $110 million in a Series B financing round that will be used to advance the company’s lead stem cell-based oncology asset into clinical trials against Acute Myeloid Leukemia and other hematological cancer targets, as well as expand the company’s development portfolio.